Registry of Lobbyists
Subject matters | Details | Categories |
---|---|---|
Health
|
C-64, An act respecting pharmacare - discussions around the structuring and implementation of a national pharmacare program.
|
Legislative Proposal, Bill or Resolution,
Policies or Program
|
Health
|
Food and Drug Act - An Act respecting food, drugs, cosmetics and therapeutic devices. Discussions relating to progressive licensing and the modernization of the Food and Drug Act.
|
Legislative Proposal, Bill or Resolution
|
Economic Development,
Health
|
Free trade treaty agreement as it relates to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to Columbia, India, and the European Union
|
Policies or Program
|
Economic Development,
Federal-Provincial Relations,
Health,
Industry
|
Intellectual Property - Changes to Patented Medicine (Notice of Compliance) (PMNOC) regulations - important regulations that can affect Eli Lilly Canada's business
|
Regulation
|
Health
|
Patent Act - An Act respecting patents of invention with regard to Intellectual Property Protection for pharmaceutical products - federal court decisions that have changed the disclosure requirements regarding the utility of an invention.
|
Legislative Proposal, Bill or Resolution
|
Economic Development,
Federal-Provincial Relations,
Health,
Industry
|
Patented Medicine Notice of Compliance (PMNOC) Regulations - enforcement of Intellectual Property with respect to the Canadian pharmaceutical industry.
|
Regulation
|
Economic Development,
Federal-Provincial Relations,
Health,
Industry
|
Patented Medicines Pricing Review Board (PMPRB) – regulations that can impact the Canadian pharmaceutical industry.
|
Regulation
|
Health,
International Trade
|
Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines.
|
Policies or Program
|
Economic Development,
Health
|
Pharmaceutical pricing policy arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
|
Policies or Program
|
Economic Development,
Federal-Provincial Relations,
Health,
Industry,
Science and Technology
|
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
|
Policies or Program
|
Subject matters | Details | Categories |
---|---|---|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Food and Drug Act - An Act respecting food, drugs, cosmetics and therapeutic devices. Discussions relating to progressive licensing and the modernization of the Food and Drug Act.
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Free trade treaty agreement as it relates to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to Columbia, India, and the European Union
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Intellectual Property - Changes to Patented Medicine (Notice of Compliance) (PMNOC) regulations - important regulations that can affect Eli Lilly Canada's business
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patent Act - An Act respecting patents of invention with regard to Intellectual Property Protection for pharmaceutical products - federal court decisions that have changed the disclosure requirements regarding the utility of an invention.
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patented Medicine Notice of Compliance (PMNOC) Regulations - enforcement of Intellectual Property with respect to the Canadian pharmaceutical industry.
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patented Medicines Pricing Review Board (PMPRB) – regulations that can impact the Canadian pharmaceutical industry.
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Pharmaceutical pricing policy arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
|
Policies or Program
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Date | DPOH, Position Title | Government Institution | Subject Matters |
---|---|---|
2025-03-20 |
|
Economic Development, Federal-Provincial Relations, Health, Industry, Science and Technology |
2025-03-07 |
|
Economic Development, Federal-Provincial Relations, Health, Industry, Science and Technology |
2024-09-24 |
|
Health |
2024-09-24 |
|
Health |
2024-09-23 |
|
Health |
2024-09-23 |
|
Health |
2024-09-12 |
|
Industry |
2024-06-27 |
|
Health |
2024-06-06 |
|
Health |
2024-06-04 |
|
Health, Industry |
2024-06-02 |
|
Health |
2024-05-24 |
|
Health |
2024-05-21 |
|
Health |
2024-05-21 |
|
Health |